WT
CRSP icon

Washington Trust’s CRISPR Therapeutics CRSP Stock Holding History

Washington Trust’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-399
Closed -$13.6K – 351
2025
Q1 		$13.6K Sell
399
-376
-49% -$15.9K ﹤0.01% 567
2024
Q4 		$30.5K Hold
775
– – ﹤0.01% 513
2024
Q3 		$36.4K Hold
775
– – ﹤0.01% 501
2024
Q2 		$41.9K Hold
775
– – ﹤0.01% 468
2024
Q1 		$52.8K Hold
775
– – ﹤0.01% 447
2023
Q4 		$48.5K Hold
775
– – ﹤0.01% 432
2023
Q3 		$35.2K Hold
775
– – ﹤0.01% 446
2023
Q2 		$43.5K Hold
775
– – ﹤0.01% 439
2023
Q1 		$35.1K Hold
775
– – ﹤0.01% 469
2022
Q4 		$31.5K Buy
775
+184
+31% +$9.76K ﹤0.01% 477
2022
Q3 		$39K Hold
591
– – ﹤0.01% 432
2022
Q2 		$36K Hold
591
– – ﹤0.01% 456
2022
Q1 		$37K Buy
591
+9
+2% +$565 ﹤0.01% 477
2021
Q4 		$44K Sell
582
-399
-41% -$34.9K ﹤0.01% 459
2021
Q3 		$109K Hold
981
– – ﹤0.01% 389
2021
Q2 		$158K Hold
981
– – ﹤0.01% 343
2021
Q1 		$119K Buy
981
+310
+46% +$46.8K ﹤0.01% 367
2020
Q4 		$103K Sell
671
-10
-1% -$1.18K ﹤0.01% 366
2020
Q3 		$57K Buy
681
+208
+44% +$18.5K ﹤0.01% 424
2020
Q2 		$35K Buy
473
+213
+82% +$12.5K ﹤0.01% 451
2020
Q1 		$11K Buy
+260
New +$13.4K ﹤0.01% 647

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Washington Trust's CRSP Position: Q2 2025 in Review

Washington Trust sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 399 shares — an estimated $13.6K sold.

Washington Trust first reported a position in CRSP in Q1 2020 and held it in 21 quarters. The position peaked at $158K in Q2 2021. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Washington Trust reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Washington Trust sold 399 CRISPR Therapeutics shares in Q2 2025, an estimated $13.6K.
  • Washington Trust first reported a position in CRISPR Therapeutics in Q1 2020 and held it in 21 quarters.
  • Washington Trust's CRISPR Therapeutics position peaked at $158K in Q2 2021.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Washington Trust's 13F filing for Q2 2025, filed 8 Aug 2025.